Multiple hyperlinks to rcsb

Your request to link to rcsb for JAK2 (aa 828-1132)

2B7A: the structural basis of janus kinase 2 inhibition by a potent and specific pan-janus kinase inhibitor (10.1182/BLOOD-2005-06-2413 )
2W1I: structure determination of aurora kinase in complex with inhibitor (10.1021/JM800984V )
2XA4: inhibitors of jak2 kinase domain (10.1021/JM1011319 )
3E62: fragment based discovery of jak-2 inhibitors (10.1016/J.BMCL.2008.08.064 )
3E63: fragment based discovery of jak-2 inhibitors (10.1016/J.BMCL.2008.08.064 )
3E64: fragment based discovery of jak-2 inhibitors (10.1016/J.BMCL.2008.08.064 )
3FUP: crystal structures of jak1 and jak2 inhibitor complexes (10.1016/J.JMB.2009.01.041 )
3IO7: 2-aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of jak2 (10.1016/J.BMCL.2009.10.053 )
3IOK: 2-aminopyrazolo[1,5-a]pyrimidines as potent and selective inhibitors of jak2 (10.1016/J.BMCL.2009.10.053 )
3JY9: janus kinase 2 inhibitors (10.1021/JM901383U )
3KCK: a novel chemotype of kinase inhibitors (10.1016/J.BMCL.2009.11.021 )
3KRR: crystal structure of jak2 complexed with a potent quinoxaline atp site inhibitor (10.1158/1535-7163.MCT-10-0053 )
3LPB: crystal structure of jak2 complexed with a potent 2,8-diaryl- quinoxaline inhibitor (10.1016/J.BMCL.2010.02.056 )
3Q32: structure of janus kinase 2 with a pyrrolotriazine inhibitor (10.1016/J.BMCL.2011.01.022 )
3RVG: crystals structure of jak2 with a 1-amino-5h-pyrido[4,3-b]indol-4- carboxamide inhibitor (10.1021/JM200909U )
3TJC: co-crystal structure of jak2 with thienopyridine 8 (10.1021/JM200911R )
3TJD: co-crystal structure of jak2 with thienopyridine 19 (10.1021/JM200911R )
3UGC: structural basis of jak2 inhibition by the type ii inhibtor nvp-bbt594 (10.1158/2159-8290.CD-11-0324 )
3ZMM: inhibitors of jak2 kinase domain (10.1016/J.BMCL.2013.02.111 )
4AQC: triazolopyridine-based inhibitor of janus kinase 2 (10.1021/JM300248Q )
4BBE: aminoalkylpyrimidine inhibitor complexes with jak2 (10.1016/J.BMCL.2012.10.007 )
4BBF: aminoalkylpyrimidine inhibitor complexes with jak2 (10.1016/J.BMCL.2012.10.007 )
4C61: inhibitors of jak2 kinase domain (10.1021/JM401546N )
4C62: inhibitors of jak2 kinase domain (10.1021/JM401546N )
4D0W: pyrrole-3-carboxamides as potent and selective jak2 inhibitors (10.1016/J.BMC.2014.06.025 )
4D0X: pyrrole-3-carboxamides as potent and selective jak2 inhibitors (10.1016/J.BMC.2014.06.025 )
4D1S: pyrrole-3-carboxamides as potent and selective jak2 inhibitors (10.1016/J.BMC.2014.06.025 )
4E4M: jak2 kinase (jh1 domain) in complex with compound 30 (10.1021/JM300438J )
4E6D: jak2 kinase (jh1 domain) triple mutant in complex with compound 7 13-jun-12 4e6d 1 title (10.1021/JM300438J )
4E6Q: jak2 kinase (jh1 domain) triple mutant in complex with compound 12 (10.1021/JM300438J )
4F08: discovery and optimization of c-2 methyl imidazo-pyrrolopyridines as potent and orally bioavailable jak1 inhibitors with selectivity over jak2 (10.1021/JM300628C )
4F09: discovery and optimization of c-2 methyl imidazo-pyrrolopyridines as potent and orally bioavailable jak1 inhibitors with selectivity over jak2 (10.1021/JM300628C )
4GFM: jak2 kinase (jh1 domain) with 2,6-dichloro-n-(2-oxo-2,5- dihydropyridin-4-yl)benzamide (10.1016/J.EJMECH.2013.03.070 )
4GL9: crystal structure of inhibitory protein socs3 in complex with jak2 kinase domain and fragment of gp130 intracellular domain (10.1038/NSMB.2519 )
4GMY: jak2 kinase (jh1 domain) in complex with 2,6-dichloro-n-{2- [(cyclopropylcarbonyl)amino]pyridin-4-yl}benzamide (10.1016/J.EJMECH.2013.03.070 )
4HGE: jak2 kinase (jh1 domain) in complex with compound 8 (10.1021/JM3012239 )
4IVA: jak2 kinase (jh1 domain) in complex with the inhibitor trans-4-[(8as)- 2-[(1r)-1-hydroxyethyl]imidazo[4,5-d]pyrrolo[2,3-b]pyridin-1(8ah)- yl]cyclohexanecarbonitrile (10.1021/JM4004895 )
4JI9: jak2 kinase (jh1 domain) in complex with tg101209 (10.1016/J.BMCL.2013.06.008 )
4JIA: jak2 kinase (jh1 domain) in complex with compound 9 (10.1016/J.BMCL.2013.06.008 )
4P7E: triazolopyridine compounds as selective jak1 inhibitors: from hit identification to glpg0634 (10.1021/JM501262Q )
4YTC: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune disease (10.1021/ACS.JMEDCHEM.5B00301 )
4YTF: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune diseases (10.1021/ACS.JMEDCHEM.5B00301 )
4YTH: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune diseases (10.1021/ACS.JMEDCHEM.5B00301 )
4YTI: discovery of vx-509 (decernotinib): a potent and selective janus kinase (jak) 3 inhibitor for the treatment of autoimmune disease (10.1021/ACS.JMEDCHEM.5B00301 )
4ZIM: crystal structure of janus kinase 2 in complex with a 9h-carbazole-1- carboxamide inhibitor (10.1016/J.BMCL.2015.04.101 )
5AEP: novel pyrrole carboxamide inhibitors of jak2 as potential treatment of myeloproliferative disorders (10.1016/J.BMC.2015.03.059 )
5CF4: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 10-ethyl-7-[(3-methoxypropyl)amino] -3-methyl-3,5,8,10- tetraazatricyclo[7.3.0.0,6] dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00225 )
5CF5: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 7-[(dimethyl-1,3-thiazol-2-yl)amino]-10-ethyl-3-methyl-3,5,8,10- tetraazatricyclo[7.3.0.02,6] dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00225 )
5CF6: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 10-[(2s)-2,3-dihydroxypropyl]-3-methyl-7-(methylamino)-3,5,8,10- tetraazatricyclo [7.3.0.02,6]dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00225 )
5CF8: crystal structure of janus kinase 2 in complex with n,n-dicyclopropyl- 10-ethyl-7-[(3-methoxypropyl)amino] -3-methyl-3,5,8,10- tetraazatricyclo[7.3.0.0,6] dodeca-1(9),2(6),4,7,11-pentaene-11- carboxamide (10.1021/ACSMEDCHEMLETT.5B00226 )
5HEZ: jak2 kinase (jh1 domain) mutant p1057a in complex with tg101209 (10.1126/SCITRANSLMED.AAG1974 )
5L3A: fragment-based discovery of 6-arylindazole jak inhibitors (10.1021/ACSMEDCHEMLETT.6B00087 )
5TQ3: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
5TQ4: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
5TQ5: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
5TQ6: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
5TQ7: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
5TQ8: design and synthesis of a pan-jak kinase inhibitor clinical candidate (pf-06263276) suitable for inhaled and topical delivery for the treatment of inflammatory diseases of the lungs and skin (10.1021/ACS.JMEDCHEM.6B01634 )
5USY: jak2 jh1 in complex with jnj-7706621 (10.1021/ACSMEDCHEMLETT.7B00153 )
5WEV: identification of an imidazopyridine scaffold to generate potent and selective tyk2 inhibitors that demonstrate activity in an in vivo psoriasis model (10.1016/J.BMCL.2017.08.022 )
6AAJ: crystal structure of jak2 in complex with peficitinib (10.1016/J.BMC.2018.08.005 )
6BBV: crystal structure of jak2 in complex with compound 25 (10.1021/ACS.JMEDCHEM.7B01598 )
6DRW: jak2 jh1 in complex with jnj-7706621 (crystal form 2)
6TPD: fragment-based discovery of pyrazolopyridones as jak1 inhibitors with excellent subtype selectivity (10.1021/ACS.JMEDCHEM.0C00359 )
6VGL: jak2 jh1 in complex with ruxolitinib (10.1021/ACS.JMEDCHEM.0C01952 )
6VN8: jak2 jh1 in complex with baricitinib (10.1021/ACS.JMEDCHEM.0C01952 )
6VNB: jak2 jh1 in complex with bl2-084 (10.1021/ACS.JMEDCHEM.0C01952 )
6VNC: jak2 jh1 in complex with bl2-096 (10.1021/ACS.JMEDCHEM.0C01952 )
6VNE: jak2 jh1 in complex with fedratinib (10.1021/ACS.JMEDCHEM.0C01952 )
6VNF: jak2 jh1 in complex with ma9-086 (10.1021/ACS.JMEDCHEM.0C01952 )
6VNG: jak2 jh1 in complex with pn2-118 (10.1021/ACS.JMEDCHEM.0C01952 )
6VNH: jak2 jh1 in complex with pn2-123 (10.1021/ACS.JMEDCHEM.0C01952 )
6VNI: jak2 jh1 in complex with pn3-115 (10.1021/ACS.JMEDCHEM.0C01952 )
6VNJ: jak2 jh1 in complex with pn4-014 (10.1021/ACS.JMEDCHEM.0C01952 )
6VNK: jak2 jh1 in complex with pn4-073 (10.1021/ACS.JMEDCHEM.0C01952 )
6VNL: jak2 jh1 in complex with sg3-179 (10.1021/ACS.JMEDCHEM.0C01952 )
6VNM: jak2 jh1 in complex with sy5-103 (10.1021/ACS.JMEDCHEM.0C01952 )
6VS3: jak2 jh1 in complex with bl2-057 (10.1021/ACS.JMEDCHEM.0C01952 )
6VSN: jak2 jh1 in complex with bl2-110 (10.1021/ACS.JMEDCHEM.0C01952 )
6WTN: human jak2 jh1 domain in complex with ruxolitinib
6WTO: human jak2 jh1 domain in complex with baricitinib
6WTP: human jak2 jh1 domain in complex with protac-intermediate linker handle 3
6WTQ: human jak2 jh1 domain in complex with protac-intermediate linker handle 4
6X8E: crystal structure of jak2 with compound 11 (10.1021/ACS.JMEDCHEM.0C00948 )
7LL4: high-resolution crystal structure of human jak2 kinase domain (jh1) bound to pn5-114.
7LL5: high-resolution crystal structure of human jak2 kinase domain (jh1) bound to pn5-150.
7Q7I: jak2 in complex with 4-{8-methoxy-2-[(1-methyl-1h-pyrazol-4-yl) amino]quinazolin-6-yl}phenol (10.1021/ACS.JMEDCHEM.1C01765 )
7Q7K: jak2 in complex with 4-(2-amino-8-methoxyquinazolin-6-yl)phenol (10.1021/ACS.JMEDCHEM.1C01765 )
7Q7L: jak2 in complex with 4-(2-amino-8-{[(2s)-1-hydroxypropan-2- yl]amino}quinazolin-6-yl)-5-ethyl-2-fluorophenol (10.1021/ACS.JMEDCHEM.1C01765 )
7Q7W: jak2 in complex with 4-(2-{[5-(dimethylamino)pentyl]amino}-8-{[(2s)-1- hydroxypropan-2-yl]amino}quinazolin-6-yl)-5-ethyl-2-fluorophenol (10.1021/ACS.JMEDCHEM.1C01765 )
7REE: high-resolution crystal structure of human jak2 kinase domain (jh1) bound to ym2-059
7RN6: high-resolution crystal structure of human jak2 kinase domain (jh1) bound to type-ii inhibitor bbt594